Drug Profile

JN 304

Alternative Names: JN-304; KB-304

Latest Information Update: 29 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Krystal Biotech
Developer Jeune; Krystal Biotech
Class Gene therapies; Skin disorder therapies
Mechanism of Action Collagen replacements; Extracellular matrix protein replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Skin disorders

Most Recent Events

24 Jul 2025 Efficacy and adverse events data from a phase I/II PEARL-2 trial in Skin disorder released by Jeune Aesthetics
28 Feb 2025 Jeune Aesthetics completes enrolment in phase-I/II clinical trials in Skin disorders in USA (Parenteral), in February 2025
20 Nov 2024 Phase-I/II clinical trials in Skin disorders in USA (Parenteral) (NCT06724900)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com